Over 1 Million ADHD Patches Recalled Due to Liner Defect

The batch was distributed between August 14, 2018 and September 5, 2018.
This error can make it difficult for patients and caregivers to remove the liners from the Daytrana patches.

Noven Therapeutics announced a voluntary recall of 6 lots of Daytrana (methylphenidate) due to the patches no longer meeting the release liner removal specification and/or z-statistic. This error can make it difficult for patients and caregivers to remove the liners from the Daytrana patches.

The affected products are as follows:

  • 10mg; Lot #80433; Exp. 08/2017; Quantity: 321,900
  • 15mg; Lot# 80426; Exp. 10/2017; Quantity: 234,960
  • 20mg; Lot #80431; Exp. 08/2017; Quantity: 182,850
  • 30mg; Lot #80442; Exp. 10/2017; Quantity: 117,000
  • 30mg; Lot #80439; Exp. 08/2017; Quantity: 113,160
  • 30mg; Lot #80438; Exp. 08/2017; Quantity: 101,790

Anyone in possession of the recalled Lot# should cease distributing and quarantine the product. Noven is notifying all wholesale and retail customers that may have received the impacted products. 

Related Articles

Daytrana, a central nervous system (CNS) stimulant, is indicated to treat attention deficit hyperactivity disorder (ADHD) in patients aged ≥6 years. It is supplied as 10mg, 15mg, 20mg, and 30mg strength transdermal patches that deliver the medication over 9 hours. 

For more information call (877) 567-7857 or visit Noven.com.